منابع مشابه
Meeting report What is new in systemic vasculitis?
From 12 to 15 April 2000 the 9th International Vasculitis/ ANCA Workshop was held at the University Hospital Groningen, The Netherlands. This series of workshops started as an informal ANCA directed workshop in 1989 in Copenhagen and has grown into an international meeting dealing with the whole spectrum of primary systemic vasculitides, including ANCA associated vasculitis. The present worksho...
متن کاملMeeting report What is new in systemic vasculitis?
From 12 to 15 April 2000 the 9th International Vasculitis/ ANCA Workshop was held at the University Hospital Groningen, The Netherlands. This series of workshops started as an informal ANCA directed workshop in 1989 in Copenhagen and has grown into an international meeting dealing with the whole spectrum of primary systemic vasculitides, including ANCA associated vasculitis. The present worksho...
متن کاملWhat is new in systemic lupus erythematosus.
Systemic lupus erythematosus is a heterogeneous rheumatic systemic disease with extremely varied clinical manifestations and a diverse pathogenesis, as illustrated in this review on the most relevant new knowledge related to the disease. Topics such as anemia, pathogenesis, cardiovascular risk assessment, antiphospholipid syndrome, prediction of damage and recent advances in treatment, includin...
متن کاملValue of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?
Although infections are a major concern in patients with primary systemic vasculitis, actual knowledge about risk factors and evidence concerning the use of anti-infective prophylaxis from clinical trials are scarce. The use of high dose glucocorticoids and cyclophosphamide pose a definite risk for infections. Bacterial infections are among the most frequent causes of death, with Staphylococcus...
متن کاملSystemic treatment in advanced soft tissue sarcoma: what is standard, what is new
For metastatic soft tissue sarcoma (STS) patients not eligible for surgery, systemic treatments, including standard chemotherapy and newer biological compounds, still play the most relevant role in the management of the disease. An anthracycline and alkylating agent combination has formed the cornerstone of chemotherapy in STS for more than 30 years, with its value over that of administration o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2000
ISSN: 0003-4967
DOI: 10.1136/ard.59.11.924